Dolutegravir
J - Antiinfectives For Systemic Use -> J05 - Antivirals For Systemic Use -> J05A - Direct Acting Antivirals -> J05AX - Other Antivirals -> J05AX12 - Dolutegravir
Administration category:
Free
Medicine group:
antiviral
Brand name:
Tivicay
Safety margins
| Weight | ROA | Dosage |
|---|---|---|
| ≥ 40 kg | ||
|
ROA: po |
Dosage: min. 50mg 1 dd to max. 50mg 2 dd |
|
Standard dosages
| Weight | ROA | Load | Dosage | |
|---|---|---|---|---|
|
ROA: po |
Load: - |
Dosage: 50mg 1 dd |
||
|
Comments:
Bij resistentie voor integraseremmer en bij combinatie met efavirenz, nevirapine, tipranavir geboost met ritonavir, of rifampicine: 50 mg 2 dd |
||||
| ≥ 40 kg | ||||
|
ROA: po |
Load: - |
Dosage: 50mg 1 dd |
||
|
Comments:
Bij resistentie voor integraseremmer en bij combinatie met efavirenz, nevirapine, tipranavir geboost met ritonavir, of rifampicine: 50 mg 2 dd |
||||
Kidney function
Renal elimination:
32%
Dosage:
independent on kidney function
Renal function-replacement therapy
CAPD: geen gegevens bekend
Hemo dialysis: geen gegevens bekend
Interactions
| Interaction with (ATC): | Expected effect: |
|---|---|
|
Interaction with (ATC): J05AG03 - Efavirenz |
Expected effect: dolutegravir 2 dd 50 mg |
|
Interaction with (ATC): J05AG01 - Nevirapine |
Expected effect: dolutegravir 2 dd 50 mg |
|
Interaction with (ATC): J05AE09 - Tipranavir |
Expected effect: dolutegravir 2 dd 50 mg |
|
Interaction with (ATC): J04AB02 - Rifampicin |
Expected effect: dolutegravir 2 dd 50 mg |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-287573.1
Updated: 06/16/2019 - 20:05
Status: Published